Literature DB >> 19299075

Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells.

Haiyan You1, Jie Jin, Huiqun Shu, Bin Yu, Angelo De Milito, Francesco Lozupone, Yun Deng, Ning Tang, Genfu Yao, Stefano Fais, Jianren Gu, Wenxin Qin.   

Abstract

One of the mechanisms of multiple drug resistance (MDR) is inappropriate sequestration of basic chemotherapeutic agents in acidic endo-lysosomes of cells. The protonation, sequestration, and secretion (PSS) model indicates that drug distribution can be affected by intracellular pH such as lysosomal pH. The vacuolar-H(+)-ATPase (V-ATPase) plays an important role in regulation of intracellular pH by pumping protons into acidic endosomes via an ATP-driven process. In this study, ATP6L, the 16kDa subunit of V-ATPase, was knocked-down by anti-ATP6L small interfering RNA (siRNA) to study the effect on chemosensitivity in the human drug-resistant breast cancer cells MCF-7/ADR. Introduction of anti-ATP6L small interfering RNA duplex into drug-resistant cancer cells significantly inhibited the expression of ATP6L mRNA and protein, as detected by qRT-PCR and Western blot. Inhibition of ATP6L expression by siRNA in MCF-7/ADR sensitized the cells to the cytotoxicity of basic chemotherapeutic agents like doxorobicin, 5-fluorourocil and vincristine. This effect was mediated by a significant increase in lysosomal pH and retention of anticancer drugs into nuclei of cells. These results support the role of tumor acidity in resistance to chemotherapy and provide a rationale for the use of tumor pH modifier agents as coadjuvants in novel anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299075     DOI: 10.1016/j.canlet.2009.02.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  38 in total

1.  Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis.

Authors:  Edgardo J Toro; Jian Zuo; David A Ostrov; Dana Catalfamo; Vivian Bradaschia-Correa; Victor Arana-Chavez; Aliana R Caridad; John K Neubert; Thomas J Wronski; Shannon M Wallet; L Shannon Holliday
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

Review 2.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

3.  TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells.

Authors:  F Lozupone; M Borghi; F Marzoli; T Azzarito; P Matarrese; E Iessi; G Venturi; S Meschini; A Canitano; R Bona; A Cara; S Fais
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

Review 4.  Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy.

Authors:  Enrico P Spugnini; Gennaro Citro; Stefano Fais
Journal:  J Exp Clin Cancer Res       Date:  2010-05-08

5.  Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.

Authors:  Kirsten Lindner; Christiane Borchardt; Maren Schöpp; Anja Bürgers; Christian Stock; Damian J Hussey; Jörg Haier; Richard Hummel
Journal:  J Exp Clin Cancer Res       Date:  2014-09-01

6.  Trafficking microenvironmental pHs of polycationic gene vectors in drug-sensitive and multidrug-resistant MCF7 breast cancer cells.

Authors:  Han Chang Kang; Olga Samsonova; You Han Bae
Journal:  Biomaterials       Date:  2010-01-21       Impact factor: 12.479

Review 7.  The Function of V-ATPases in Cancer.

Authors:  Laura Stransky; Kristina Cotter; Michael Forgac
Journal:  Physiol Rev       Date:  2016-07       Impact factor: 37.312

8.  pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.

Authors:  Danielle S W Benoit; Scott M Henry; Andrew D Shubin; Allan S Hoffman; Patrick S Stayton
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

9.  Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion.

Authors:  Vera Michel; Yamhilette Licon-Munoz; Kristina Trujillo; Marco Bisoffi; Karlett J Parra
Journal:  Int J Cancer       Date:  2012-09-21       Impact factor: 7.396

Review 10.  Role of lysosomes in physiological activities, diseases, and therapy.

Authors:  Ziqi Zhang; Pengfei Yue; Tianqi Lu; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2021-05-14       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.